MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + Tremelimumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Malignancies
Conditions
Advanced Solid Malignancies
Trial Timeline
Jun 5, 2017 → Dec 16, 2022
NCT ID
NCT03084471About MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + Tremelimumab
MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + Tremelimumab is a phase 3 stage product being developed by AstraZeneca for Advanced Solid Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT03084471. Target conditions include Advanced Solid Malignancies.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Malignancies were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03084471 | Phase 3 | Completed |
Competing Products
20 competing products in Advanced Solid Malignancies